Enasidenib Mesylate
Brand name: Idhifa
Rank #438 of 500 drugs by total cost
$18.1M
Total Cost
554
Total Claims
$18.1M
Total Cost
36
Prescribers
$33K
Cost per Claim
0
Beneficiaries
554
30-Day Fills
$503K
Avg Cost/Provider
15
Avg Claims/Provider
About Enasidenib Mesylate
Enasidenib Mesylate (sold as Idhifa) was prescribed 554 times by 36 Medicare Part D providers in 2023, costing the program $18.1M. At $33K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 435 | Elapegademase-Lvlr (Revcovi) | $19.0M | 52 |
| 436 | Methylprednisolone (Methylprednisolone) | $18.9M | 1,934,494 |
| 437 | Sacrosidase (Sucraid) | $18.5M | 1,517 |
| 438 | Enasidenib Mesylate (Idhifa) | $18.1M | 554 |
| 439 | Posaconazole (Posaconazole) | $18.0M | 7,163 |
| 440 | Metronidazole (Metronidazole) | $18.0M | 405,967 |
| 441 | Rufinamide (Rufinamide) | $18.0M | 8,793 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology